Viloxazine, a relatively new treatment for attention-deficit/hyperactivity disorder (ADHD), has gained attention due to its novel mechanism of action and potential benefits for ADHD patients. Initially developed as an antidepressant in the 1970s, pharmaceutical companies reintroduced and repurposed it in 2021 as a non-stimulant medication for ADHD under the brand name Qelbree. You can also …